Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 43-56

  Ciancio, G ^a   Mattiazzi, A ^a   Miller, J ^a   Burke, G W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Graft rejection; Immunosuppressive agents; Kidney transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGRAFT; ALPHA CHAIN; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; REVIEW; T LYMPHOCYTE ACTIVATION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CALCINEURIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; REOPERATION; RISK FACTORS; TIME FACTORS;

EID: 0037773349     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs 2001;15:655-66.
2. Berard JL, Velez RL, Freeman RB, Tsunoda SM. A review of interleukin receptor antagonists in solid organ transplantation. Pharmacotherapy 1999;19:1127-37.
3. Wiseman LR, Faulds D. Daclizumab. A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999;58:1029-42.
4. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab. A review of its use in the management of organ transplantation. BioDrugs 2001;15:745-73.
5. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
6. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplants recipients. Drugs 1999;58:1029-42.
7. Vicenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997;63:33-8.
8. Vicenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998;30:2155-8.
9. Nashan B, Light S, Hardie IR, Lin A, Johson R for the Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999;67:110-5.
10. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002;73:1100-6.
11. Ciancio G, Miller A, Burke GW, Gharagozloo H, Rosen A, Roth D et al. Daclizumab induction, for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil and steroids as maintenance immunosuppression. Transplant Proc 2001;33:1013-4.
12. Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vicenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000;13:151-9.
13. Bumgardner GL, Hardie I, Johnson RWG, Lin A, Nashan B, Pescovitz MD et al. Results of 3-y phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001;72:839-45.
14. Gaston RS, Deirhoi MH, Patterson T, Prastofer E, Julian BA, Barber WH et al. OKT3 first dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991;39:141-8.
15. Vicenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS. Pentoxifylline doses not prevent the cytokine-induced first dose reaction following OKT3: a randomized, double-blind placebo-controlled study. Transplantation 1996;61:573-7.
16. Ciancio G, Burke GW, Suzart K, Vaidya A, Roth D, Kupin W et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil and steroids as maintenance immunosuppression. Transplant Proc 2003;35:873-4.
17. Iverson AJ, Vick SC, Sarnacki CT, Wright FH jr. Daclizumab in live donor renal transplantation. Transplant Proc 2000;32:790-2.
18. Vincenti F. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Transplant Proc 1999;31:2206-7.
19. Ivanoski N, Popov Z, Cakalaroski G, Spasovski G, Sikole A, Paneva-Masin J. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation. Transplant Proc 2001;33:3203-4.
20. ter Meulen CG, van Riemsdijk I, Hene RJ, Hilbrands LB, Baan CC, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged IL-2Rα-chain blockade. Am J Transplant 2001;1:276.
21. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Rα-chain blockade. Transplantation 2001;72:1709-10.
22. Vincenti F, Lantz MV, Birnbaum JL, Tomlanovich SJ, Amend WJC, Adey DB et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplant patients. Am J Transpant 2001;1:385.
23. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002;2:568-73.
24. Deierhoi MH, Hudson SL, Gaston RS. Clinical experience with two dose regimen of daclizumab in cadaveric renal transplantation. Transplantation 2000;69: S260.
25. Lácha J, Simová M, Nosková L, Teplan V, Vitko S. Zenapax versus KOT-3 prophylaxis in immunologically high-risk kidney transplant recipients. Transplant Proc 2001;33:2273-4.
26. Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S. Anti-interleukin 2-receptor antibodies in kidney transplantation: preliminary results. Transplant Proc 2000;32:2623-5.
27. Meier-Kriesche HU, Kaza H, Palekar SS, Friedman GS, Mulgaonkar SP, Ojo AO et al. The effect of daclizumb in a high-risk renal transplant population. Clin Transplant 2000;14:509-13.
28. Meier-Kriesche HU, Palekar SS, Friedman GS, Mulgaonkar SP, Goldblat MV, Kaplan B. Efficacy of daclizumab in an African-American and Hispanic renal transplant population. Transpl Int 2000;13:142-5.
29. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A et al. Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. Transplant Proc 2002;34:1617-8.
30. Pirsh JD, Miller J, Deierhoi MH, Vicenti F, Filo R. Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-83.
31. Sollinger HW, for the US Renal Transpmant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
32. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc 2001;33:1000-1.
33. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7.
34. Tran HTB, Acharya MK, Mckay DB, Sayegh MH, Carpenter CB, Auchincloss H jr et al. Avoidance of cyclosporine in renal transplantation: effects of daclizimab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000:11:1903-9.
35. Weimar W, van Riemsdijk IC, Smak Gregoor PJH, van Gelder T. Anti-CD25 prophylaxis allows steroid free kidney transplantation. Transplant Proc 2001;33:3176-7.
36. Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001;72:845-50.
37. Hong JC, Kahan BD. Use of anti-cd25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 1999;68:701-4.
38. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-cd25 mAB provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000;14:550-4.
39. Cantorovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-cd25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid oran transplant patients with acute renal dysfunction. Transplantation 2002;73:1169-72.
40. Kahan BD, Rajagopalan PR, Hall M for the United States Simulet Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basilimab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999;67:276-84.
41. Nair MP, Nampoory MRN, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W et al. Induction immunosuppression with interleukin-2 receptor antibodies (Basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001;33:2767-9.
42. Nampoory MRN, Abdulhalim M, Johny KV, Al-Jawad Donia FA, Nair MP, Said T et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventinal ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 2002;34: 2916-9.
43. Olyaei AJ, Thi K, deMattos AM, Bennett M. Use of basiliximab and daclizumab in kidney transplantation. Progr Transplant 2001;11:33-9.
44. Mattiazzi A, Ciancio G, Burke GW, Suzart K, Roth D, Kupin W et al. The use of daclizumab as induction therapy in combination with tacrolimus, mycophenolate mofetil in patients with previous transplants. Transplantation 2002;74:467.
45. Ettenger RB. New immunosuppressive agents in pediatric renal transplantation. Transplant Proc 1998;30: 1956-8.
46. Samsonov D, Briscoe DM. Long-term care of pediatric renal transplant patients: from bench to bedside. Curr Opin Pediatr 2002;14:205-10.
47. Savo AM, Book BK, Henson S, Hakimi, Pescovitz MD. Daclizumab rapidly saturates interleukin-2-receptor-α (CD25) on lymph node lymphocytes in children. Transplant Proc 1999;31:1182-3.
48. Ciancio G, Burke GW, Suzart K, Mattiazzi A, Rosen A, Zilleruello G et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant Proc 2002;34:1944-5.
49. Nevins T, Ettenger R, Potter D, Pescovitz M, Knechtle S, Colombani P et al. Daclizumab (Zenapax) in pediatric renal allografts: final data. Transplantation 1999;67: S124.
50. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13-21.
51. Burke GW, Ciancio G, Olson L, Roth D, Miller J. Teny survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. Transplant Proc 2001;33:1681-3.
52. Burke GW, Ciancio G, Figueiro J, Olson L, Gomez C, Rosen A et al. Can acute rejection be prevented in spk transplantation. Transplant Proc 2002;34:1913-4.
53. Burke GW, Ciando G, Figueiro J, Olson L, Gomez C, Rosen A et al. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen. Transplant Proc 2002;34: 1918-9.
54. Stratta RJ, Alloway RR, Lo A, Hodge E. A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis. Transplant Proc 2001;33: 1692-3.
55. Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP et al. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. Transplant Proc 2001;33:1701-3.
56. Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001;72: 1637-43.
57. Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP et al. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transplant Int 2001;14:396-404.
58. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in combination with tacrolimus, mycophenolate mofetit, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: 6-month interim analysis. Transplant Proc 2002;34:1903-5.
59. Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 2002;16:60-8.
60. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000;69:1867-72.
61. Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001;7:20-5.
62. Markus BH, Weber S, Allers C, Hauser I, Encke A. Daclizumab induction therapy in combination with tacrolimus. Transplant Proc 2001;33:1418-9.
63. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002;73:1640-6.
64. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002;2:454-60.
65. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetit. Transplantation 2001;72: 1675-9.
66. Figueras J, Bernardos A, Prieto M, Gómez M, Rimola A, Ortiz de Urbina J et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002;34:1511-3.
67. Heffron TG, Smallwood GA, Pillen T, Davis L, Martinez E, Romero R et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002;34:1514-5.
68. Pinna AD, Ricordi C, Weppler D, Ruiz P, Tzakis AG. Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab. Transplant Proc 2001;33: 1087-9.
69. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff B et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with monoclonal antibody. N Engl J Med 2000;342:613-9.
70. Garrity ER jr, Villanueva J, Bhorade S, Husain A, Vigneswaran WT. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 recpetor antibody. Transplantation 2001;71:773-7.
71. Pinna AD, Weppler D, Nery JR, Khan F, Ruiz P, Kato T et al. Induction therapy for clinical intestinal transplantation: comparison of four different regimens. Transplant Proc 2000;32:1193-4.
72. Tzakis AG, Kato T, Nishida S, Mittal N, Neff G, Nery J et al. Evolution of gastrointestinal transplantation at the University of Miami. Transplant Proc 2001;33:1545-9.